Abstract:Objective:To investigate the difference in survival time and response rate of patients with advanced non small cell lung cancer (NSCLC) in different smoking status before and after Gefitinib treatment. Methods:Our study population consisted of 305 patients with advance NSCLC from MD Anderson Cancer Center and Shanghai Chest Hospital between 2000 Dec and 2003 Oct. All patients had smoking history and received Gefitinib 250 mg/d. Survival curves were plotted by Kaplan-Meier method and compared by logrank test. Cox multivariate regression model was used to examine the prognostic significance of covariates on survival rates. The difference between patients with different smoking status was done by χ2 test. Logistic regression was used for multivariate analysis of disease control rates and response rates. All reported Ps are two-sided and statistical significance was defined as P0.05. Results:Out of 305 patients with advanced NSCLC,99 patients (32.46%) still smoked and 206 patients (67.54%) ceased smoking when they came into hospital. The mean survival time (MST) of all the patients was 5.47 month(95%CI:4.58-6.35); the median progression free survival (PFS) time was 3.43 month(95%CI:2.75-4.12). Females were associated with a better PFS than males(9.47 month vs 4.43 month;P0.001). The survival rate in younger patients was higher than older patients (9.80 month vs 5.13 month,P=0.013). The survival rate in patients with 0-1 PS score was higher than those with 2-3 PS score (6.47 month vs 5.10 month,P=0.045). The survival time was longer in patients with light smoking status (15.37 month for 400 pack-year, 6.23 month for 400-799 pack-year, 5.33 month for 800-1199 pack-year,5.10 month for 1200 pack-year,P=0.035). Cox regression analysis demonstrated gender (P=0.004), age (P=0.008), and PS score(P=0.064) were independent factors affecting survival rate and gender(P=0.033) and probably PS score(P=0.014) independently affected the PFS. Totally 242 patients were evaluable including 10 cases of partial response (4.13%), 69 cases of stable disease (28.51%), 163 cases of disease progression (67.36%). The objective response rate was 4.13% and the disease control rate was 32.64%. Logistic regression did not show any independent factor affecting response rate and disease control rate. Conclusion:Light smoking status and Gefitinib treatment were associated with higher survival rate. Influence of smoking status on survival rate of patients with advanced NSCLC needs further investigation.

Impact of Smoking on the Clinical Efficacy of Gefitinib Combined with Radiotherapy after Chemotherapy Failure in the Patients with Stages III and IV Non-Small-cell Lung Cancer

A Comparison of Efficacy and Toxicity Between Never-Smokers and Smokers with Lung Adenocarcinoma after Concurrent Gefitinib and Thoracic Radiotherapy

Influence of Smoking on the Efficency of Gefitinib in the Treatment of Advanced Non Small Cell Lung Cancer

Impact of Smoking Status on EGFR-TKI Efficacy for Advanced Non-Small-cell Lung Cancer in EGFR Mutants: a Meta-Analysis.

Impact of Smoking Status on the Efficacy of Epidermal Growth Factor Receptor-Tyrosine Kinase Inhibitors Plus Anti-Vascular Endothelial Growth Factor Antibodies in Non-Small Cell Lung Cancer: A Systematic Review and Meta-Analysis

Impacts of Smoking on the Efficacy of Epidermal Growth Factor Tyrosine Kinase Inhibitors in Patients with Advanced Non-small Cell Lung Cancer

Egfr Mutations and the Correlation with Gefitinib Therapy in Chinese Nsclc - A Systematic Review Based on Individual Patient Data from 5 Medical Centers in China.

Prediction of Epidermal Growth Factor Receptor Mutations in the Plasma/pleural Effusion to Efficacy of Gefitinib Treatment in Advanced Non-Small Cell Lung Cancer.

Gefitinib or Erlotinib Vs Chemotherapy for EGFR Mutation-Positive Lung Cancer: Individual Patient Data Meta-Analysis of Overall Survival

Relationship Between Mutations of Epidermal Growth Factor Receptor in the Plasma and Pleural Effusion and Responses to Gefitinib in Advanced Pretreated Non-Small Cell Lung Cancer

Effect of smoking habits on the efficacy of EGFR-TKI plus anti-angiogenic agent in advanced EGFR-mutant NSCLC

Impact of Specific Epidermal Growth Factor Receptor (EGFR) Mutations and Clinical Characteristics on Outcomes after Treatment with EGFR Tyrosine Kinase Inhibitors Versus Chemotherapy in EGFR-Mutant Lung Cancer: A Meta-Analysis.

Effect Of Egfr Mutations On Gefitinib In Advanced Previous Treated Non-Small-Cell Lung Cancer

The Impact of Smoking Status on the Progression‐free Survival of Non‐small Cell Lung Cancer Patients Receiving Molecularly Target Therapy or Immunotherapy Versus Chemotherapy: A Meta‐analysis

Final Overall Survival and Updated Biomarker Analysis Results from the Randomized Phase Iii Icogen Trial

Intercalating and Maintenance Gefitinib Plus Chemotherapy Versus Chemotherapy Alone in Selected Advanced Non-Small Cell Lung Cancer with Unknown EGFR Status.

Clinical Efficiency of Gefitinib in the Treatment of Patients with Advanced Non-Small Cell Lung Cancer

Relationship between epidermal growth factor receptor gene mutation and the efficacy of gefitinib in the treatment of advanced nonsmall-cell lung cancer

Impact of Gefitinib on 41 Selected Non-small-cell Lung Cancer Patients and Their Serum CEA

Effect of gene mutation of epidermal growth factor receptor on targeting therapy of advanced non-small cell lung cancer